MorphoSys AG Company Overview
About MorphoSys AG
MorphoSys (ETR:MOR), (NASDAQ:MOR) is a biotechnology company focused on the development of innovative antibody therapies for the treatment of cancer and autoimmune diseases. It is traded on the NASDAQ stock exchange under the ticker code NASDAQ:MOR. The company leverages its proprietary technology platforms to design and develop monoclonal antibodies, aiming to bring novel treatments to patients who have limited treatment options. MorphoSys has a diverse pipeline of therapeutic candidates in various stages of clinical development, alongside strategic partnerships with leading pharmaceutical companies to advance and commercialize its therapies. The company's objectives include advancing its research and development capabilities, expanding its product pipeline, and achieving global commercial success with its innovative therapeutic solutions.
Snapshot
Operations
Products and/or services of MorphoSys AG
- Monjuvi (tafasitamab) - A CD19-directed cytolytic antibody for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
- Pelabresib - An investigational small molecule targeting BET proteins for myelofibrosis.
- Gantenerumab - A collaboration with Roche, an anti-amyloid beta antibody for Alzheimer's disease.
- Tremfya (guselkumab) - Licensed to Janssen, a human anti-IL-23 monoclonal antibody for psoriasis.
- Otilimab - An anti-GM-CSF monoclonal antibody for rheumatoid arthritis, in partnership with GSK.
- Felzartamab (MOR202) - A human monoclonal antibody targeting CD38 for multiple myeloma and autoimmune diseases.
MorphoSys AG executive team
- Ms. Charlotte LohmannChief Legal and Human Resources Officer & Member of Management Board
- Mr. Arkadius Pichota M.B.A., Ph.D.Chief Executive Officer
- Mr. Lukas GilgenChief Financial Officer
- Dr. Tim Demuth M.D., Ph.D.Chief Research & Development Officer
- Mr. Klaus De WallHead of Accounting & Tax
- Dr. Margit UrbanHead of Discovery Alliances & Technologies
- Dr. Julia Neugebauer Ph.D.Head of Investor Relations
- Dr. Barbara Krebs-Pohl Ph.D.Chief Business Officer
- Dr. Günter WellnhoferHead of Technical Operations
- Dr. Harald WatzkaHead of Alliance Management